{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T11:17:49Z","timestamp":1787743069324,"version":"build-2784847793"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00066-026-02564-7","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:52:45Z","timestamp":1783705965000},"page":"911-920","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ultrahypofractionation of localized prostate cancer\u2014an updated statement of the prostate cancer working group of the German Society of Radiation Oncology (DEGRO)"],"prefix":"10.1007","volume":"202","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6539-0682","authenticated-orcid":false,"given":"A.-C.","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. M.","family":"Aebersold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Albrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Boehmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Ganswindt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.-S.","family":"Schmidt-Hegemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"H\u00f6cht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. A.","family":"Koerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Niehoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. C.","family":"Peeken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pinkawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Polat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Shelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. K. B.","family":"Spohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zamboglou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Zips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"2564_CR1","unstructured":"S3-Leitlinie Prostatakarzinom Version 8.1 - August 2025 AWMF-Registernummer: 043-022OL. https:\/\/www.leitlinienprogramm-onkologie.de\/fileadmin\/user_upload\/2025-08-22_LL_Prostatakarzinom_Langversion_8.1.pdf"},{"issue":"15","key":"2564_CR2","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","volume":"375","author":"JL Donovan","year":"2016","unstructured":"Donovan\u00a0JL, Hamdy\u00a0FC, Lane\u00a0JA, Mason\u00a0M, Metcalfe\u00a0C, Walsh\u00a0E, Blazeby\u00a0JM, Peters\u00a0TJ, Holding\u00a0P, Bonnington\u00a0S, Lennon\u00a0T, Bradshaw\u00a0L, Cooper\u00a0D, Herbert\u00a0P, Howson\u00a0J, Jones\u00a0A, Lyons\u00a0N, Salter\u00a0E, Thompson\u00a0P, Tidball\u00a0S, Blaikie\u00a0J, Gray\u00a0C, Bollina\u00a0P, Catto\u00a0J, Doble\u00a0A, Doherty\u00a0A, Gillatt\u00a0D, Kockelbergh\u00a0R, Kynaston\u00a0H, Paul\u00a0A, Powell\u00a0P, Prescott\u00a0S, Rosario\u00a0DJ, Rowe\u00a0E, Davis\u00a0M, Turner\u00a0EL, Martin\u00a0RM, Neal\u00a0DE (2016) Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 375(15):1425\u20131437. https:\/\/doi.org\/10.1056\/NEJMoa1606221","journal-title":"N Engl J Med"},{"issue":"17","key":"2564_CR3","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","volume":"388","author":"FC Hamdy","year":"2023","unstructured":"Hamdy\u00a0FC, Donovan\u00a0JL, Lane\u00a0JA, Metcalfe\u00a0C, Davis\u00a0M, Turner\u00a0EL, Martin\u00a0RM, Young\u00a0GJ, Walsh\u00a0EI, Bryant\u00a0RJ, Bollina\u00a0P, Doble\u00a0A, Doherty\u00a0A, Gillatt\u00a0D, Gnanapragasam\u00a0V, Hughes\u00a0O, Kockelbergh\u00a0R, Kynaston\u00a0H, Paul\u00a0A, Paez\u00a0E, Powell\u00a0P, Rosario\u00a0DJ, Rowe\u00a0E, Mason\u00a0M, Catto\u00a0JWF, Peters\u00a0TJ, Oxley\u00a0J, Williams\u00a0NJ, Staffurth\u00a0J, Neal\u00a0DE (2023) Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med 388(17):1547\u20131558. https:\/\/doi.org\/10.1056\/NEJMoa2214122","journal-title":"N Engl J Med"},{"issue":"5","key":"2564_CR4","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/s0360-3016(98)00438-6","volume":"43","author":"DJ Brenner","year":"1999","unstructured":"Brenner\u00a0DJ, Hall\u00a0EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Hydrogen Energy 43(5):1095\u20131101. https:\/\/doi.org\/10.1016\/s0360-3016(98)00438-6","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2564_CR5","unstructured":"National Comprehensive Cancer Network Guidelines (2025) NCCN Guidelines for Treatment of Cancer by Site. www.nccn.org"},{"issue":"3","key":"2564_CR6","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/ju.0000000000000071","volume":"201","author":"SC Morgan","year":"2019","unstructured":"Morgan\u00a0SC, Hoffman\u00a0K, Loblaw\u00a0DA, Buyyounouski\u00a0MK, Patton\u00a0C, Barocas\u00a0D, Bentzen\u00a0S, Chang\u00a0M, Efstathiou\u00a0J, Greany\u00a0P, Halvorsen\u00a0P, Koontz\u00a0BF, Lawton\u00a0C, Leyrer\u00a0CM, Lin\u00a0D, Ray\u00a0M, Sandler\u00a0H (2019) Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO and AUA Evidence-Based Guideline. The Journal of urology 201(3):528\u2013534. https:\/\/doi.org\/10.1097\/ju.0000000000000071","journal-title":"The Journal of urology"},{"issue":"2","key":"2564_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00066-020-01723-8","volume":"197","author":"F Wolf","year":"2021","unstructured":"Wolf\u00a0F, Sedlmayer\u00a0F, Aebersold\u00a0D, Albrecht\u00a0C, B\u00f6hmer\u00a0D, Flentje\u00a0M, Ganswindt\u00a0U, Ghadjar\u00a0P, H\u00f6cht\u00a0S, H\u00f6lscher\u00a0T, M\u00fcller\u00a0AC, Niehoff\u00a0P, Pinkawa\u00a0M, Schmidt-Hegemann\u00a0NS, Zamboglou\u00a0C, Zips\u00a0D, Wiegel\u00a0T (2021) Ultrahypofractionation of localized prostate cancer : Statement from the DEGRO working group prostate cancer. Strahlenther Onkol 197(2):89\u201396. https:\/\/doi.org\/10.1007\/s00066-020-01723-8","journal-title":"Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft [et al]"},{"issue":"2","key":"2564_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/s1470-2045(20)30581-7","volume":"22","author":"P Fransson","year":"2021","unstructured":"Fransson\u00a0P, Nilsson\u00a0P, Gunnlaugsson\u00a0A, Beckman\u00a0L, Tavelin\u00a0B, Norman\u00a0D, Thellenberg-Karlsson\u00a0C, Hoyer\u00a0M, Lagerlund\u00a0M, Kindblom\u00a0J, Ginman\u00a0C, Johansson\u00a0B, Bj\u00f6rnlinger\u00a0K, Seke\u00a0M, Agrup\u00a0M, Zackrisson\u00a0B, Kjell\u00e9n\u00a0E, Franz\u00e9n\u00a0L, Widmark\u00a0A (2021) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. Lancet Oncol 22(2):235\u2013245. https:\/\/doi.org\/10.1016\/s1470-2045(20)30581-7","journal-title":"Lancet Oncol"},{"issue":"10196","key":"2564_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/s0140-6736(19)31131-6","volume":"394","author":"A Widmark","year":"2019","unstructured":"Widmark\u00a0A, Gunnlaugsson\u00a0A, Beckman\u00a0L, Thellenberg-Karlsson\u00a0C, Hoyer\u00a0M, Lagerlund\u00a0M, Kindblom\u00a0J, Ginman\u00a0C, Johansson\u00a0B, Bj\u00f6rnlinger\u00a0K, Seke\u00a0M, Agrup\u00a0M, Fransson\u00a0P, Tavelin\u00a0B, Norman\u00a0D, Zackrisson\u00a0B, Anderson\u00a0H, Kjell\u00e9n\u00a0E, Franz\u00e9n\u00a0L, Nilsson\u00a0P (2019) Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5\u2011year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet 394(10196):385\u2013395. https:\/\/doi.org\/10.1016\/s0140-6736(19)31131-6","journal-title":"Lancet"},{"issue":"11","key":"2564_CR10","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/s1470-2045(19)30569-8","volume":"20","author":"DH Brand","year":"2019","unstructured":"Brand\u00a0DH, Tree\u00a0AC, Ostler\u00a0P, van der Voet\u00a0H, Loblaw\u00a0A, Chu\u00a0W, Ford\u00a0D, Tolan\u00a0S, Jain\u00a0S, Martin\u00a0A, Staffurth\u00a0J, Camilleri\u00a0P, Kancherla\u00a0K, Frew\u00a0J, Chan\u00a0A, Dayes\u00a0IS, Henderson\u00a0D, Brown\u00a0S, Cruickshank\u00a0C, Burnett\u00a0S, Duffton\u00a0A, Griffin\u00a0C, Hinder\u00a0V, Morrison\u00a0K, Naismith\u00a0O, Hall\u00a0E, van As\u00a0N (2019) Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial. Lancet Oncol 20(11):1531\u20131543. https:\/\/doi.org\/10.1016\/s1470-2045(19)30569-8","journal-title":"Lancet Oncol"},{"issue":"10","key":"2564_CR11","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1016\/s1470-2045(22)00517-4","volume":"23","author":"AC Tree","year":"2022","unstructured":"Tree\u00a0AC, Ostler\u00a0P, van der Voet\u00a0H, Chu\u00a0W, Loblaw\u00a0A, Ford\u00a0D, Tolan\u00a0S, Jain\u00a0S, Martin\u00a0A, Staffurth\u00a0J, Armstrong\u00a0J, Camilleri\u00a0P, Kancherla\u00a0K, Frew\u00a0J, Chan\u00a0A, Dayes\u00a0IS, Duffton\u00a0A, Brand\u00a0DH, Henderson\u00a0D, Morrison\u00a0K, Brown\u00a0S, Pugh\u00a0J, Burnett\u00a0S, Mahmud\u00a0M, Hinder\u00a0V, Naismith\u00a0O, Hall\u00a0E, van As\u00a0N (2022) Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2\u2011year toxicity results from an open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 23(10):1308\u20131320. https:\/\/doi.org\/10.1016\/s1470-2045(22)00517-4","journal-title":"Lancet Oncol"},{"issue":"15","key":"2564_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","volume":"391","author":"N van As","year":"2024","unstructured":"van As\u00a0N, Griffin\u00a0C, Tree\u00a0A, Patel\u00a0J, Ostler\u00a0P, van der Voet\u00a0H, Loblaw\u00a0A, Chu\u00a0W, Ford\u00a0D, Tolan\u00a0S, Jain\u00a0S, Camilleri\u00a0P, Kancherla\u00a0K, Frew\u00a0J, Chan\u00a0A, Naismith\u00a0O, Armstrong\u00a0J, Staffurth\u00a0J, Martin\u00a0A, Dayes\u00a0I, Wells\u00a0P, Price\u00a0D, Williamson\u00a0E, Pugh\u00a0J, Manning\u00a0G, Brown\u00a0S, Burnett\u00a0S, Hall\u00a0E (2024) Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer. N Engl J Med 391(15):1413\u20131425. https:\/\/doi.org\/10.1056\/NEJMoa2403365","journal-title":"N Engl J Med"},{"key":"2564_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.07.007","author":"R Ratnakumaran","year":"2025","unstructured":"Ratnakumaran\u00a0R, Brand\u00a0DH, Sasitharan\u00a0A, Mohajer\u00a0J, Hinder\u00a0V, Khan\u00a0A, Mayet\u00a0H, Loblaw\u00a0A, Hall\u00a0E, van As\u00a0N, Tree\u00a0AC (2025) Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE\u2011B Study. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.eururo.2025.07.007","journal-title":"European urology"},{"issue":"31","key":"2564_CR14","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1200\/jco.2013.51.1972","volume":"31","author":"A Pollack","year":"2013","unstructured":"Pollack\u00a0A, Walker\u00a0G, Horwitz\u00a0EM, Price\u00a0R, Feigenberg\u00a0S, Konski\u00a0AA, Stoyanova\u00a0R, Movsas\u00a0B, Greenberg\u00a0RE, Uzzo\u00a0RG, Ma\u00a0C, Buyyounouski\u00a0MK (2013) Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer. J\u00a0Clin Oncol 31(31):3860\u20133868. https:\/\/doi.org\/10.1200\/jco.2013.51.1972","journal-title":"J Clin Oncol"},{"issue":"5","key":"2564_CR15","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/j.ijrobp.2024.05.014","volume":"120","author":"DAS Toesca","year":"2024","unstructured":"Toesca\u00a0DAS, Hartsell\u00a0WF, DeWees\u00a0TA, Chang\u00a0JH, Laughlin\u00a0BS, Voss\u00a0MM, Dodoo\u00a0CA, Mohammed\u00a0N, Keole\u00a0SR, McGee\u00a0LA, Gondi\u00a0V, Sweeney\u00a0PJ, Dorn\u00a0P, Sinesi\u00a0CC, Doh\u00a0LS, Rich\u00a0T, Vargas\u00a0CE (2024) Stereotactic Body Proton Therapy Versus Conventionally Fractionated Proton Therapy for Early Prostate Cancer: A Randomized, Controlled, Phase 3 Trial. Adv Radiat Oncol 120(5):1377\u20131385. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.05.014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2564_CR16","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ijrobp.2022.04.006","volume":"113","author":"W Kwan","year":"2022","unstructured":"Kwan\u00a0W, Bahl\u00a0G, Kim\u00a0D, Ye\u00a0A, Gagne\u00a0I, Alexander\u00a0A (2022) Acute Toxicity of Ultrahypofractionation Compared With Moderate Hypofractionation in Prostate Cancer Treatment: A Randomized Trial. Adv Radiat Oncol 113(5):1036\u20131043. https:\/\/doi.org\/10.1016\/j.ijrobp.2022.04.006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2564_CR17","doi-asserted-by":"publisher","first-page":"S4414","DOI":"10.1016\/S0167-8140(25)04191-X","volume":"206","author":"P Nilsson","year":"2025","unstructured":"Nilsson\u00a0P, Gunnlaugsson\u00a0A, Beckman\u00a0L, Widmark\u00a0A, Fransson\u00a0P, Hoyer\u00a0M, Lagerlund\u00a0M, Kindblom\u00a0J, Johansson\u00a0B, Bj\u00f6rnlinger\u00a0K, Ginman\u00a0C, Olsson\u00a0M, Agrup\u00a0M, Kjell\u00e9n\u00a0E, Zackrisson\u00a0B, Anderson\u00a0H, Tavelin\u00a0B, Franz\u00e9n\u00a0L, Karlsson\u00a0CT (2025) 4981 Ultra-hypofractionated radiotherapy for localised prostate cancer: 10-year outcomes of the HYPO-RT-PC phase 3 trial (ISRCTN45905321). Radiotherapy and Oncology 206:S4414\u2013S4415. https:\/\/doi.org\/10.1016\/S0167-8140(25)04191-X","journal-title":"Radiotherapy and Oncology"},{"issue":"1","key":"2564_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-023-04714-3","volume":"42","author":"W Lilleby","year":"2024","unstructured":"Lilleby\u00a0W, Kishan\u00a0A, Geinitz\u00a0H (2024) Acute and long-term toxicity in primary hypofractionated external photon radiation therapy in patients with localized prostate cancer. World J Urol 42(1):41. https:\/\/doi.org\/10.1007\/s00345-023-04714-3","journal-title":"World journal of urology"},{"issue":"12","key":"2564_CR19","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/s1470-2045(22)00544-7","volume":"23","author":"JM Martin","year":"2022","unstructured":"Martin\u00a0JM, Richardson\u00a0M, Siva\u00a0S, Cardoso\u00a0M, Handmer\u00a0M, Sidhom\u00a0M (2022) Mechanisms, mitigation, and management of urinary toxicity from prostate radiotherapy. Lancet Oncol 23(12):e534\u2013e543. https:\/\/doi.org\/10.1016\/s1470-2045(22)00544-7","journal-title":"Lancet Oncol"},{"issue":"3","key":"2564_CR20","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/s1470-2045(24)00720-4","volume":"26","author":"J Nikitas","year":"2025","unstructured":"Nikitas\u00a0J, Jamshidian\u00a0P, Tree\u00a0AC, Hall\u00a0E, Dearnaley\u00a0D, Michalski\u00a0JM, Lee\u00a0WR, Nguyen\u00a0PL, Sandler\u00a0HM, Catton\u00a0CN, Lukka\u00a0HR, Incrocci\u00a0L, Heemsbergen\u00a0W, Pos\u00a0FJ, Roy\u00a0S, Malone\u00a0S, Horwitz\u00a0E, Wong\u00a0JK, Arcangeli\u00a0S, Sanguineti\u00a0G, Romero\u00a0T, Sun\u00a0Y, Steinberg\u00a0ML, Valle\u00a0LF, Weidhaas\u00a0JB, Spratt\u00a0D, Telesca\u00a0D, Kishan\u00a0AU (2025) The interplay between acute and late toxicity among patients receiving prostate radiotherapy: an individual patient data meta-analysis of six randomised trials. Lancet Oncol 26(3):378\u2013386. https:\/\/doi.org\/10.1016\/s1470-2045(24)00720-4","journal-title":"Lancet Oncol"},{"key":"2564_CR21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2340\/sju.v58.7719","volume":"58","author":"O Lilleby","year":"2023","unstructured":"Lilleby\u00a0O, Meidahl Petersen\u00a0P, Daugaard\u00a0G, Anne Perell\u00a0K (2023) Current evidence for moderate and ultra-hypofractionated radiation therapy in prostate cancer: a summary of the results from phase 3 randomised trials. Scand J Urol 58:21\u201327. https:\/\/doi.org\/10.2340\/sju.v58.7719","journal-title":"Scand J Urol"},{"issue":"4","key":"2564_CR22","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.ijrobp.2024.07.2142","volume":"120","author":"R Ratnakumaran","year":"2024","unstructured":"Ratnakumaran\u00a0R, Zilli\u00a0T (2024) Toxicity After Prostate Radiation Therapy: Addressing the Transurethral Resection of the Prostate (TURP) Challenge. Adv Radiat Oncol 120(4):1021\u20131023. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.07.2142","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"2564_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00555","volume":"10","author":"A Pepin","year":"2020","unstructured":"Pepin\u00a0A, Aghdam\u00a0N, Shah\u00a0S, Kataria\u00a0S, Tsou\u00a0H Jr, Datta\u00a0S, Danner\u00a0M, Ayoob\u00a0M, Yung\u00a0T, Lei\u00a0S, Gurka\u00a0M, Collins\u00a0BT, Krishnan\u00a0P, Suy\u00a0S, Hankins\u00a0R, Lynch\u00a0JH, Collins\u00a0SP (2020) Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP). Front Oncol 10:555. https:\/\/doi.org\/10.3389\/fonc.2020.00555","journal-title":"Frontiers in oncology"},{"issue":"1","key":"2564_CR24","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13014-015-0351-6","volume":"10","author":"MK Gurka","year":"2015","unstructured":"Gurka\u00a0MK, Chen\u00a0LN, Bhagat\u00a0A, Moures\u00a0R, Kim\u00a0JS, Yung\u00a0T, Lei\u00a0S, Collins\u00a0BT, Krishnan\u00a0P, Suy\u00a0S, Dritschilo\u00a0A, Lynch\u00a0JH, Collins\u00a0SP (2015) Hematuria following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer. Radiat Oncol 10(1):44\u201344. https:\/\/doi.org\/10.1186\/s13014-015-0351-6","journal-title":"Radiation Oncology"},{"issue":"2","key":"2564_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ijrobp.2009.11.023","volume":"79","author":"AA Aizer","year":"2011","unstructured":"Aizer\u00a0AA, Anderson\u00a0NS, Oh\u00a0SC, Yu\u00a0JB, McKeon\u00a0AM, Decker\u00a0RH, Peschel\u00a0RE (2011) The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy. Adv Radiat Oncol 79(2):379\u2013384. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.11.023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2564_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s12094-015-1371-2","volume":"18","author":"R Mazzola","year":"2016","unstructured":"Mazzola\u00a0R, Fersino\u00a0S, Fiorentino\u00a0A, Ricchetti\u00a0F, Giaj Levra\u00a0N, Di Paola\u00a0G, Sicignano\u00a0G, Naccarato\u00a0S, Ruggieri\u00a0R, Alongi\u00a0F (2016) The impact of prostate gland dimension in genitourinary toxicity after definitive prostate cancer treatment with moderate hypofractionation and volumetric modulated arc radiation therapy. Clin Transl Oncol 18(3):317\u2013321. https:\/\/doi.org\/10.1007\/s12094-015-1371-2","journal-title":"Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico"},{"issue":"2","key":"2564_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100805","volume":"7","author":"D Natesan","year":"2022","unstructured":"Natesan\u00a0D, Carpenter\u00a0DJ, Floyd\u00a0W, Oyekunle\u00a0T, Niedzwiecki\u00a0D, Waters\u00a0L, Godfrey\u00a0D, Moravan\u00a0MJ, Lee\u00a0WR, Salama\u00a0JK (2022) Effect of Large Prostate Volume on Efficacy and Toxicity of Moderately Hypofractionated Radiation Therapy in Patients With Prostate Cancer. Adv Radiat Oncol 7(2):100805. https:\/\/doi.org\/10.1016\/j.adro.2021.100805","journal-title":"Advances in radiation oncology"},{"issue":"5","key":"2564_CR28","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamaoncol.2021.0039","volume":"7","author":"C Greco","year":"2021","unstructured":"Greco\u00a0C, Pares\u00a0O, Pimentel\u00a0N, Louro\u00a0V, Santiago\u00a0I, Vieira\u00a0S, Stroom\u00a0J, Mateus\u00a0D, Soares\u00a0A, Marques\u00a0J, Freitas\u00a0E, Coelho\u00a0G, Seixas\u00a0M, Lopez-Beltran\u00a0A, Fuks\u00a0Z (2021) Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial. JAMA Oncol 7(5):700\u2013708. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0039","journal-title":"JAMA Oncol"},{"issue":"12","key":"2564_CR29","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1007\/s00345-023-04663-x","volume":"41","author":"WL Ong","year":"2023","unstructured":"Ong\u00a0WL, Loblaw\u00a0A (2023) The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer-Quo Vadimus? World J Urol 41(12):3485\u20133491. https:\/\/doi.org\/10.1007\/s00345-023-04663-x","journal-title":"World journal of urology"},{"key":"2564_CR30","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-025-02388-x","author":"SKB Spohn","year":"2025","unstructured":"Spohn\u00a0SKB, Aebersold\u00a0DM, Albrecht\u00a0C, Boehmer\u00a0D, Ganswindt\u00a0U, Schmidt-Hegemann\u00a0NS, Hoecht\u00a0S, H\u00f6lscher\u00a0T, Koerber\u00a0SA, Mueller\u00a0AC, Niehoff\u00a0P, Peeken\u00a0JC, Pinkawa\u00a0M, Polat\u00a0B, Shelan\u00a0M, Wolf\u00a0F, Zamboglou\u00a0C, Zips\u00a0D, Wiegel\u00a0T (2025) Biomarkers in prostate cancer: current status and future directions in radiotherapy-statement from the Prostate Cancer Working Group of the German Society of Radiation Oncology (DEGRO). Strahlenther Onkol. https:\/\/doi.org\/10.1007\/s00066-025-02388-x","journal-title":"Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft"},{"issue":"3","key":"2564_CR31","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1515\/raon-2016-0036","volume":"50","author":"AC M\u00fcller","year":"2016","unstructured":"M\u00fcller\u00a0AC, Mischinger\u00a0J, Klotz\u00a0T, Gagel\u00a0B, Habl\u00a0G, Hatiboglu\u00a0G, Pinkawa\u00a0M (2016) Interdisciplinary consensus statement on indication and application of a hydrogel spacer for prostate radiotherapy based on experience in more than 250 patients. Radiol Oncol 50(3):329\u2013336. https:\/\/doi.org\/10.1515\/raon-2016-0036","journal-title":"Radiology and oncology"},{"key":"2564_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.phro.2024.100662","volume":"32","author":"M Murr","year":"2024","unstructured":"Murr\u00a0M, Wegener\u00a0D, B\u00f6ke\u00a0S, Gani\u00a0C, M\u00f6nnich\u00a0D, Niyazi\u00a0M, Schneider\u00a0M, Zips\u00a0D, M\u00fcller\u00a0AC, Thorwarth\u00a0D (2024) Comparison of online adaptive and non-adaptive magnetic resonance image-guided radiation therapy in prostate cancer using dose accumulation. Phys Imaging Radiat Oncol 32:100662. https:\/\/doi.org\/10.1016\/j.phro.2024.100662","journal-title":"Physics and imaging in radiation oncology"},{"key":"2564_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.652678","volume":"11","author":"SKB Spohn","year":"2021","unstructured":"Spohn\u00a0SKB, Sachpazidis\u00a0I, Wiehle\u00a0R, Thomann\u00a0B, Sigle\u00a0A, Bronsert\u00a0P, Ruf\u00a0J, Benndorf\u00a0M, Nicolay\u00a0NH, Sprave\u00a0T, Grosu\u00a0AL, Baltas\u00a0D, Zamboglou\u00a0C (2021) Influence of Urethra Sparing on Tumor Control Probability and Normal Tissue Complication Probability in Focal Dose Escalated Hypofractionated Radiotherapy: A Planning Study Based on Histopathology Reference. Front Oncol 11:652678. https:\/\/doi.org\/10.3389\/fonc.2021.652678","journal-title":"Frontiers in oncology"},{"issue":"3","key":"2564_CR34","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.eururo.2021.12.012","volume":"82","author":"VH Groen","year":"2022","unstructured":"Groen\u00a0VH, Haustermans\u00a0K, Pos\u00a0FJ, Draulans\u00a0C, Isebaert\u00a0S, Monninkhof\u00a0EM, Smeenk\u00a0RJ, Kunze-Busch\u00a0M, de Boer\u00a0JCJ, van der Voort van Zijp\u00a0J, Kerkmeijer\u00a0LGW, van der Heide\u00a0UA (2022) Patterns of Failure Following External Beam Radiotherapy With or Without an Additional Focal Boost in the Randomized Controlled FLAME Trial for Localized Prostate Cancer. Eur Urol Oncol 82(3):252\u2013257. https:\/\/doi.org\/10.1016\/j.eururo.2021.12.012","journal-title":"European urology"},{"key":"2564_CR35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.radonc.2021.12.027","volume":"167","author":"VH Groen","year":"2022","unstructured":"Groen\u00a0VH, van Schie\u00a0M, Zuithoff\u00a0NPA, Monninkhof\u00a0EM, Kunze-Busch\u00a0M, de Boer\u00a0JCJ, van der Voort van Zijp\u00a0J, Pos\u00a0FJ, Smeenk\u00a0RJ, Haustermans\u00a0K, Isebaert\u00a0S, Draulans\u00a0C, Depuydt\u00a0T, Verkooijen\u00a0HM, van der Heide\u00a0UA, Kerkmeijer\u00a0LGW (2022) Urethral and bladder dose-effect relations for late genitourinary toxicity following external beam radiotherapy for prostate cancer in the FLAME trial. Clin Transl Radiat Oncol 167:127\u2013132. https:\/\/doi.org\/10.1016\/j.radonc.2021.12.027","journal-title":"Radiother Oncol"},{"key":"2564_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225795","author":"C Zamboglou","year":"2021","unstructured":"Zamboglou\u00a0C, Spohn\u00a0SKB, Adebahr\u00a0S, Huber\u00a0M, Kirste\u00a0S, Sprave\u00a0T, Gratzke\u00a0C, Chen\u00a0RC, Carl\u00a0EG, Weber\u00a0WA, Mix\u00a0M, Benndorf\u00a0M, Wiegel\u00a0T, Baltas\u00a0D, Jenkner\u00a0C, Grosu\u00a0AL (2021) PSMA-PET\/MRI-Based Focal Dose Escalation in Patients with Primary Prostate Cancer Treated with Stereotactic Body Radiation Therapy (HypoFocal-SBRT): Study Protocol of a Randomized, Multicentric Phase III Trial. Cancers. https:\/\/doi.org\/10.3390\/cancers13225795","journal-title":"Cancers (Basel)"},{"key":"2564_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110568","author":"C Draulans","year":"2024","unstructured":"Draulans\u00a0C, Haustermans\u00a0K, Pos\u00a0FJ, van der Heide\u00a0UA, De Cock\u00a0L, van der Voort van Zyp\u00a0J, De Boer\u00a0H, Smeenk\u00a0RJ, Kunze-Busch\u00a0M, Monninkhof\u00a0EM, De Roover\u00a0R, Isebaert\u00a0S, Kerkmeijer\u00a0LGW (2024) Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5\u2011year efficacy and toxicity in the hypo-FLAME trial. Clin Transl Radiat Oncol. https:\/\/doi.org\/10.1016\/j.radonc.2024.110568","journal-title":"Radiotherapy and Oncology"},{"key":"2564_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2025.110883","volume":"208","author":"SKB Spohn","year":"2025","unstructured":"Spohn\u00a0SKB, Zamboglou\u00a0C, B\u00fcrkle\u00a0SL, Freitag\u00a0MT, Brumberg\u00a0J, Engel\u00a0H, Gainey\u00a0M, Kamps\u00a0M, Toncheva\u00a0P, Sprave\u00a0T, Kirste\u00a0S, Sigle\u00a0A, Jilg\u00a0C, Gratzke\u00a0C, Adebahr\u00a0S, Mix\u00a0M, Bamberg\u00a0F, Zschaeck\u00a0S, Ghadjar\u00a0P, Baltas\u00a0D, Grosu\u00a0AL (2025) Safety and quality of life of PSMA-PET- and MRI-based focal dose escalated radiotherapy for intermediate- and high-risk prostate cancer: Primary endpoint analysis of the bi-centric phase II HypoFocal trial (ARO2020-01). Clin Transl Radiat Oncol 208:110883. https:\/\/doi.org\/10.1016\/j.radonc.2025.110883","journal-title":"Radiother Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02564-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-026-02564-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-026-02564-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:20:14Z","timestamp":1787739614000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-026-02564-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["2564"],"URL":"https:\/\/doi.org\/10.1007\/s00066-026-02564-7","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"value":"0179-7158","type":"print"},{"value":"1439-099X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.-C.\u00a0M\u00fcller, D.\u00a0M.\u00a0Aebersold, C.\u00a0Albrecht, D.\u00a0Boehmer, U.\u00a0Ganswindt, N.-S.\u00a0Schmidt-Hegemann, S.\u00a0H\u00f6cht, E.\u00a0Hoffmann, T.\u00a0H\u00f6lscher, S.\u00a0A.\u00a0Koerber, P.\u00a0Niehoff, J.C.\u00a0Peeken, M.\u00a0Pinkawa, B.\u00a0Polat, M.\u00a0Shelan, S.K.B.\u00a0Spohn, F.\u00a0Wolf, C.\u00a0Zamboglou, D.\u00a0Zips, and T.\u00a0Wiegel declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this article no studies with human participants or animals were performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical standards","group":{"name":"EthicsHeading","label":"Declarations"}}]}}